Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2B6 and Efavirenz‐Containing Antiretroviral Therapy

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

The human immunodeficiency virus (HIV) type-1 non-nucleoside reverse transcriptase inhibitor, efavirenz, is widely used to treat HIV-1 infection. Efavirenz is predominantly metabolized into inactive metabolites by CYP2B6, and patients with certain CYP2B6 genetic variants may be at increased risk for adverse effects, particularly central nervous system toxicity and treatment discontinuation. We summarize the evidence from the literature and provide therapeutic recommendations for efavirenz prescribing based on CYP2B6 genotypes.

Related collections

Author and article information

Journal

Title: Clinical Pharmacology & Therapeutics

Abbreviated Title: Clin. Pharmacol. Ther.

Publisher: Wiley

ISSN (Print): 0009-9236

ISSN (Electronic): 1532-6535

Publication date Created: April 29 2019

Publication date Created: October 2019

Publication date (Electronic): July 05 2019

Publication date (Print): October 2019

Volume: 106

Issue: 4

Pages: 726-733

Affiliations

[1 ]Department of MedicineDivision of Clinical PharmacologyIndiana University School of Medicine Indianapolis Indiana USA

[2 ]Department of Pharmacy PracticeMassachusetts College of Pharmacy and Health Sciences University School of Pharmacy Boston Massachusetts USA

[3 ]Department of Pharmaceutical SciencesSt. Jude Children's Research Hospital Memphis Tennessee USA

[4 ]Department of Biomedical Data ScienceStanford University Stanford California USA

[5 ]Department of Infectious DiseasesSt. Jude Children's Research Hospital Memphis Tennessee USA

[6 ]Division of Pharmacogenomics and Personalized MedicineFaculty of Medicine Ramathibodi HospitalDepartment of PathologyMahidol University Bangkok Thailand

[7 ]Laboratory for PharmacogenomicsFaculty of Medicine Ramathibodi HospitalSomdech Phra Debaratana Medical Center Bangkok Thailand

[8 ]Department of Pharmacy and Genomic Medicine InstituteCleveland Clinic Cleveland Ohio USA

[9 ]Department of Diagnostic & Biomedical SciencesThe University of Texas Health Sciences Center School of Dentistry Houston Texas USA

[10 ]Centre for Addiction and Mental HealthUniversity of Toronto Toronto Ontario Canada

[11 ]African Institute of Biomedical Science & TechnologyWilkins Hospital Harare Zimbabwe

[12 ]Division of Pharmaceutical SciencesFairleigh Dickinson University School of Pharmacy Florham Park New Jersey USA

[13 ]Department of Internal MedicineMeharry Medical College School of Medicine Nashville Tennessee USA

[14 ]Division of Infectious DiseasesEmory University School of Medicine Atlanta Georgia USA

[15 ]Division of Clinical Pharmacology, Toxicology, & Therapeutic InnovationChildren's Mercy Kansas City Kansas City Missouri USA

[16 ]Departments of Medicine, Pharmacology, Pathology, Microbiology, & ImmunologyVanderbilt University School of Medicine Nashville Tennessee USA

Article

DOI: 10.1002/cpt.1477

PMC ID: 6739160

PubMed ID: 31006110

SO-VID: 6556892f-2937-484d-8259-6fa2394899b2

License:

http://onlinelibrary.wiley.com/termsAndConditions#vor

http://doi.wiley.com/10.1002/tdm_license_1.1

History

Data availability:

Comments

Comment on this article

scite_

Cited by 54

See all cited by

- Version 1
- Version 1